Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
暂无分享,去创建一个
B. Grosbois | I. Yakoub-Agha | M. Mohty | S. Leyvraz | P. Moreau | H. Avet-Loiseau | G. Marit | C. Mathiot | T. Facon | J. Harousseau | C. Doyen | M. Attal | C. Berthou | L. Garderet | C. Chaleteix | M. Wetterwald | C. Hulin | D. Caillot | L. Benboubker | F. Garban | T. Lamy | M. Michallet | J. Jaubert | P. Casassus | M. Dib | C. Traullé | J. Fuzibet | B. Kolb | V. Dorvaux
[1] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[2] R. Fonseca,et al. Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach , 2007, Molecular Cancer Therapeutics.
[3] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[4] L. Escoda,et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis , 2007, Leukemia.
[5] R. Wieser,et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion , 2007, Leukemia.
[6] L. Kmet,et al. Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial. , 2006 .
[7] Serge Leyvraz,et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.
[8] J. Bourhis,et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.
[9] M. Baccarani,et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Bataille,et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. , 2006, Blood.
[11] G. Ahmann,et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.
[12] S. Trudel,et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Coiffier,et al. Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). , 2004 .
[14] F. Mandelli,et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. , 2004, Blood.
[15] P. L. Bergsagel,et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. , 2004, Blood.
[16] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[17] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[18] F. Zhan,et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.
[19] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[20] R. Bataille,et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.
[21] P. L. Bergsagel,et al. Chromosome translocations in multiple myeloma , 2001, Oncogene.
[22] L. Baldini,et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.
[23] R. Bataille,et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.
[24] R. Bataille,et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.
[25] R. Bataille,et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. , 1998, Cancer research.
[26] P. L. Bergsagel,et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.
[27] M. Taniwaki,et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.
[28] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[29] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .